Publisher
Springer Science and Business Media LLC
Reference10 articles.
1. DiNardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617–629
2. Ucciero A, Pagnoni F, Scotti L et al (2023) Venetoclax with Hypomethylating agents in newly diagnosed Acute myeloid leukemia: a systematic review and Meta-analysis of Survival Data from Real-World studies. Cancers (Basel) 15(18):4618
3. Niscola P, Mazzone C, Fratoni S et al (2023) Acute myeloid leukemia with NPM1 mutation and disseminated Leukemia Cutis: achievement of Molecular Complete Remission by Venetoclax/Azacitidine Combination in a very old patient. Acta Haematol 146(5):408–412
4. Ehsan H, Iqbal Q, Masood A, Grunwald MR (2022) Durable remission of acute myeloid leukemia in an elderly patient following a limited course of azacitidine and venetoclax. Leuk Res Rep 18:100345
5. Chua CC, Hammond D, Kent A, Tiong IS et al (2022) Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia. Blood Adv 6(13):3879–3883